Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Race Disparities Plague Treatment And Outcomes In Health Care
CNN examines race disparities in health care during a 4-minute segment that is part of the station"s week-long focus on health care issues.
generic viagra online
Six Researchers To Receive Prestigious Awards From The American Society Of Hematology
The American Society of Hematology (ASH), the world"s largest professional society of blood specialists, will honor six scientists who have made significant contributions to the understanding of hematologic diseases. These awards, including the newly created Ernest Beutler Lecture and Prize, will be presented at the 51st ASH Annual Meeting taking place December 5-8 in New Orleans.
News of the day
Gene Network Sciences Announces Broad Cancer Collaboration With UCSF And Initial Results
Gene Network Sciences, Inc. (GNS) announced that it has entered into a research collaboration with the University of California San Francisco Cancer Center (UCSF) aimed at accelerating cancer research and drug development across several therapeutic areas. This collaboration will combine the clinical and research oncology expertise of UCSF with the computational expertise and supercomputer-driven REFS(TM) platform of GNS. Financial terms of the agreement were not disclosed.
Cardiovascular

New Data From Endeavor-II Challenges Conventional Wisdom On Drug-Eluting Stents

New clinical data presented at a major international meeting of interventional cardiologists challenged the conventionalwisdom on the long-term efficacy of drug-eluting stents, medical devices used in the treatment of coronary artery disease. In ENDEAVOR-II (n=1,197), a randomized controlled trial comparing Medtronic"s (NYSE: MDT) Endeavor drugeluting stent (DES) to its Driver baremetal stent (BMS), patients treated with the Endeavor DES required fewer repeat procedures at five years postimplant than many observers and analysts would have expected based on the results of other trials with comparable designs. With clinical data from ENDEAVORII now through five years of followup, the Endeavor DES continues to show a distinctively low and durable plateau in the rate of target lesion revascularization (TLR), a standard measure of efficacy for coronary stents. As presented today at EuroPCR09 in a latebreaking clinical trials session by Dr. David Kandzari of the Scripps Clinic in La Jolla, Calif., the TLR rate in this seminal DES trial at five years is 7.5 percent, only a 0.3 percent difference from the rate at three and four years. "The longterm performance of the Endeavor stent is really remarkable," said Dr. Kandzari. "There is an especially unique consistency and durability in lateterm TLR that is distinct from alternative DES programs." Safety has long been the Endeavor stent"s hallmark, with exceptionally low rates of complications including very late stent thrombosis to five years across various geographies, patient subsets and trial designs. These latest results confirm that the Endeavor stent"s longterm safety is complemented by longterm efficacy. "The Endeavor stent continues to distinguish itself with a strong record of sustained safety and clinical efficacy," said Sean Salmon, vice president and general manager of Medtronic CardioVascular"s Coronary and Peripheral business. "From preclinical research and clinical imaging studies, we believe that the Endeavor stent"s proven biocompatibility contributes to complete and functional healing early on and positve longterm outcomes for patients." This long term data also will be submitted in a premarket approval (PMA) application for review by the U.S. Food and Drug Administration. Medtronic


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

Copyright 2009